Skip to main content

Gemini Therapeutics, Inc. (GMTX)

NASDAQ: GMTX · IEX Real-Time Price · USD
4.30
-0.05 (-1.15%)
After-hours:Sep 24, 2021 7:52 PM EDT
4.35
-0.06 (-1.36%)
At close: Sep 24, 4:00 PM
Market Cap187.53M
Revenue (ttm)n/a
Net Income (ttm)-76.33M
Shares Out43.11M
EPS (ttm)-3.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume96,804
Open4.35
Previous Close4.41
Day's Range4.32 - 4.48
52-Week Range3.22 - 19.09
Betan/a
Analystsn/a
Price Target22.00 (+405.7%)
Est. Earnings Daten/a

About GMTX

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.

IndustryBiotechnology
Founded2015
Employees29
Stock ExchangeNASDAQ
Ticker SymbolGMTX
Full Company Profile

Financial Performance

Financial Statements

News

Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement The...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

2 weeks ago - Business Wire

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at E...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

2 weeks ago - Business Wire

Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

2 weeks ago - Business Wire

Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock?

Investors need to pay close attention to Gemini Therapeutics (GMTX) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at C...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

3 weeks ago - Business Wire

Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...

1 month ago - Business Wire

Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

1 month ago - Business Wire

Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atro...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degen...

3 months ago - Business Wire

3 Biotech Stocks With Big Catalysts in June

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.

Other symbols:CRBPNTLA
3 months ago - The Motley Fool

Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

3 months ago - Business Wire

Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...

4 months ago - Business Wire

Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatm...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...

4 months ago - Business Wire

Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

4 months ago - Business Wire

Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthal...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

4 months ago - Business Wire

Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

5 months ago - Business Wire

Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

5 months ago - Business Wire

Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

5 months ago - Business Wire

Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

7 months ago - Business Wire

3 of the Latest Companies to Go Public Via SPACs

SPACs dominated Wall Street in 2020. The backwards IPOs of these three companies suggests that 2021 will be more of the same.

Other symbols:APPHHIMS
7 months ago - InvestorPlace

Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMD

Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degeneration (AMD) ...

7 months ago - Benzinga

Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

7 months ago - Business Wire

Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...

7 months ago - Business Wire